Literature DB >> 17682125

Epstein-Barr virus latent membrane protein 2A is a B-cell receptor mimic and essential for B-cell survival.

Christoph Mancao1, Wolfgang Hammerschmidt.   

Abstract

Many cells latently infected with Epstein-Barr virus (EBV), including certain virus-associated tumors, express latent membrane protein 2A (LMP2A), suggesting an important role for this protein in viral latency and oncogenesis. LMP2A mimics B-cell receptor signaling but can also act as a decoy receptor blocking B-cell receptor (BCR) activation. Studies of peripheral B cells have not resolved this apparent contradiction because LMP2A seems to be dispensable for EBV-induced transformation of these B cells in vitro. We show here that LMP2A is essential for growth transformation of germinal center B cells, which do not express the genuine BCR because of deleterious somatic hypermutations in their immunoglobulin genes. BCR-positive (BCR(+)) and BCR-negative (BCR(-)) B cells are readily transformed with a recombinant EBV encoding a conditional, floxed LMP2A allele, but the survival and continued proliferation of both BCR(+) and BCR(-) B cells is strictly dependent on LMP2A. These findings indicate that LMP2A has potent, distinct antiapoptotic and/or transforming characteristics and point to its role as an indispensable BCR mimic in certain B cells from which human B-cell tumors such as Hodgkin lymphoma originate.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17682125      PMCID: PMC2077319          DOI: 10.1182/blood-2007-05-090142

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  38 in total

1.  Growth inhibition and DNA damage induced by Cre recombinase in mammalian cells.

Authors:  A Loonstra; M Vooijs; H B Beverloo; B A Allak; E van Drunen; R Kanaar; A Berns; J Jonkers
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-31       Impact factor: 11.205

2.  Control of Epstein-Barr virus reactivation by activated CD40 and viral latent membrane protein 1.

Authors:  Barbara Adler; Eveline Schaadt; Bettina Kempkes; Ursula Zimber-Strobl; Barbara Baier; Georg W Bornkamm
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-18       Impact factor: 11.205

3.  EBV persistence in memory B cells in vivo.

Authors:  G J Babcock; L L Decker; M Volk; D A Thorley-Lawson
Journal:  Immunity       Date:  1998-09       Impact factor: 31.745

4.  Ability of the hydrophobic FGF and basic TAT peptides to promote cellular uptake of recombinant Cre recombinase: a tool for efficient genetic engineering of mammalian genomes.

Authors:  Michael Peitz; Kurt Pfannkuche; Klaus Rajewsky; Frank Edenhofer
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-19       Impact factor: 11.205

5.  Glycoprotein gp110 of Epstein-Barr virus determines viral tropism and efficiency of infection.

Authors:  B Neuhierl; R Feederle; W Hammerschmidt; H J Delecluse
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-30       Impact factor: 11.205

6.  The Epstein-Barr virus latent membrane protein 2A PY motif recruits WW domain-containing ubiquitin-protein ligases.

Authors:  M Ikeda; A Ikeda; L C Longan; R Longnecker
Journal:  Virology       Date:  2000-03-01       Impact factor: 3.616

7.  Latent membrane protein 2A of Epstein-Barr virus binds WW domain E3 protein-ubiquitin ligases that ubiquitinate B-cell tyrosine kinases.

Authors:  G Winberg; L Matskova; F Chen; P Plant; D Rotin; G Gish; R Ingham; I Ernberg; T Pawson
Journal:  Mol Cell Biol       Date:  2000-11       Impact factor: 4.272

8.  The immunoreceptor tyrosine-based activation motif of Epstein-Barr virus LMP2A is essential for blocking BCR-mediated signal transduction.

Authors:  S Fruehling; R Longnecker
Journal:  Virology       Date:  1997-09-01       Impact factor: 3.616

9.  Tonsillar memory B cells, latently infected with Epstein-Barr virus, express the restricted pattern of latent genes previously found only in Epstein-Barr virus-associated tumors.

Authors:  G J Babcock; D A Thorley-Lawson
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-24       Impact factor: 11.205

10.  Epstein-Barr virus coopts lipid rafts to block the signaling and antigen transport functions of the BCR.

Authors:  M L Dykstra; R Longnecker; S K Pierce
Journal:  Immunity       Date:  2001-01       Impact factor: 31.745

View more
  94 in total

Review 1.  EBV Persistence--Introducing the Virus.

Authors:  David A Thorley-Lawson
Journal:  Curr Top Microbiol Immunol       Date:  2015       Impact factor: 4.291

2.  Role for HLA in susceptibility to infectious mononucleosis.

Authors:  Paul J Farrell
Journal:  J Clin Invest       Date:  2007-10       Impact factor: 14.808

3.  Epstein-Barr virus latent membrane protein 2A enhances MYC-driven cell cycle progression in a mouse model of B lymphoma.

Authors:  Kamonwan Fish; Jia Chen; Richard Longnecker
Journal:  Blood       Date:  2013-10-30       Impact factor: 22.113

Review 4.  The biology of Hodgkin's lymphoma.

Authors:  Ralf Küppers
Journal:  Nat Rev Cancer       Date:  2008-12-11       Impact factor: 60.716

Review 5.  How I treat classical Hodgkin lymphoma in patients infected with human immunodeficiency virus.

Authors:  Thomas S Uldrick; Richard F Little
Journal:  Blood       Date:  2014-12-11       Impact factor: 22.113

6.  Epstein-Barr virus latent membrane protein 2A exploits Notch1 to alter B-cell identity in vivo.

Authors:  Leah J Anderson; Richard Longnecker
Journal:  Blood       Date:  2008-09-24       Impact factor: 22.113

7.  Toll-like receptor agonists synergistically increase proliferation and activation of B cells by epstein-barr virus.

Authors:  Stefanie Iskra; Markus Kalla; Henri-Jacques Delecluse; Wolfgang Hammerschmidt; Andreas Moosmann
Journal:  J Virol       Date:  2010-01-20       Impact factor: 5.103

8.  B Cell-Intrinsic STING Signaling Triggers Cell Activation, Synergizes with B Cell Receptor Signals, and Promotes Antibody Responses.

Authors:  Melissa M Walker; Bergren W Crute; John C Cambier; Andrew Getahun
Journal:  J Immunol       Date:  2018-10-03       Impact factor: 5.422

9.  Epstein-Barr virus LMP2A accelerates MYC-induced lymphomagenesis.

Authors:  R Bultema; R Longnecker; M Swanson-Mungerson
Journal:  Oncogene       Date:  2009-02-02       Impact factor: 9.867

10.  EBV-positive Hodgkin lymphoma is associated with suppression of p21cip1/waf1 and a worse prognosis.

Authors:  Ting-Yun Liu; Shang-Ju Wu; Mi-Hsin Huang; Fei-Yun Lo; Mong-Hsun Tsai; Ching-Hwa Tsai; Su-Ming Hsu; Chung-Wu Lin
Journal:  Mol Cancer       Date:  2010-02-09       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.